The Oxford University genetic sequencing spinout is reportedly mulling an IPO that would provide exits to investors including commercialisation firm IP Group.
Oxford Nanopore Technologies, a UK-based genetic sequencing technology developer spun out from University of Oxford, is considering floating its shares in an initial public offering (IPO), The Telegraph has reported.
Founded in 2005, Oxford Nanopore has developed real-time DNA and RNA sequencing technology that offers biological analyses at a relatively low cost. It has applications in disease and pathogen surveillance, environmental monitoring, food supply chain inspection and microgravity biology.
The company markets portable, desktop and large-scale models of its technology. It is set to be used in clinical trials for the first time, to diagnose bacterial infections at University of Bern’s Institute for Infectious Diseases, and for genetic testing of Huntington’s disease at health system Guys and St Thomas’ NHS Trust.
Commercialisation firm IP Group has an 18% stake in the company that is expected to be worth about $355m, based on the reported $2.1bn valuation at…
